Search

• Synflorix™, GlaxoSmithKline’s pneumococcal vaccine, receives European authorisation

  Media

  Protection now possible against three pneumococcal strains not covered by currently available vaccine.

  https://www.gsk.com/en-gb/media/press-releases/synflorix-glaxosmithkline-s-pneumococcal-vaccine-receives-european-authorisation/

  First published: 31 March 2009

• GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries

  Media

  GSK today announced that it has signed an agreement with WHO to donate 50 million doses of its influenza vaccine.

  https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-with-the-who-to-donate-50-million-doses-of-pandemic-h1n1-vaccine-for-distribution-to-developing-countries/

  First published: 09 November 2009

• GSK Update: GSK’s Arepanrix™ H1N1 pandemic vaccine prequalified by the World Health Organization

  Media

  First prequalification for an H1N1 pandemic vaccine

  https://www.gsk.com/en-gb/media/press-releases/gsk-update-gsk-s-arepanrix-h1n1-pandemic-vaccine-prequalified-by-the-world-health-organization/

  First published: 30 November 2009

• GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older

  Media

  An approval from the US Food and Drug Administration’s (FDA) Center

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-months-and-older/

  First published: 18 November 2016

• GSK’s paediatric pneumococcal candidate vaccine Synflorix™ receives positive opinion in Europe

  Media

  Serotypes included in the vaccine are responsible for up to 90% of invasive pneumoccal disease in young children in Europe. 1,2,3

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-paediatric-pneumococcal-candidate-vaccine-synflorix-receives-positive-opinion-in-europe/

  First published: 21 January 2009

• GSK to support manufacture of Novavax’ COVID-19 vaccine

  Media

  GSK to support manufacture of up to 60 million doses of Novavax’ COVID-19 vaccine.

  https://www.gsk.com/en-gb/media/press-releases/gsk-to-support-manufacture-of-novavax-covid-19-vaccine/

  First published: 29 March 2021

• Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

  Media

  Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine.

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-join-forces-in-unprecedented-vaccine-collaboration-to-fight-covid-19/

  First published: 14 April 2020

• GSK starts Phase III RSV candidate vaccine programme for older adults

  Media

  Positive Phase I/II results established the robust immunogenicity of the vaccine candidate in the target population

  https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-rsv-candidate-vaccine-programme-for-older-adults/

  First published: 16 February 2021

• Arexvy, GSK’s Respiratory Syncytial Virus (RSV) vaccine, receives positive European Medicines Agency CHMP opinion for adults aged 50-59 at increased risk for RSV disease

  Media

  If approved, this will be the first vaccine in the EU for adults aged 50-59 who are at increased risk of RSV disease.

  https://www.gsk.com/en-gb/media/press-releases/arexvy-receives-positive-ema-chmp-opinion-for-adults-aged-50-59-at-increased-risk-for-rsv-disease/

  First published: 29 July 2024

• GlaxoSmithKline update: Government orders for pandemic (H1N1) 2009 vaccine

  Media

  GSK is committed to supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-government-orders-for-pandemic-h1n1-2009-vaccine/

  First published: 06 October 2009